Small molecule glucagon release inhibitors with activity in human islets

Small molecule glucagon release inhibitors with activity in human islets

PurposeType 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the im...

Full description

Bibliographic Details
Main Authors: Michael A. Kalwat, Karina Rodrigues-dos-Santos, Derk D. Binns, Shuguang Wei, Anwu Zhou, Matthew R. Evans, Bruce A. Posner, Michael G. Roth, Melanie H. Cobb
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Endocrinology
Subjects:
glucagon
alpha cell
chemical biology
high-throughput (HT) screening
Type 1 diabetes (T1D)
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1114799/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1114799/full

Similar Items